WO2006062424A2 - Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system - Google Patents
Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system Download PDFInfo
- Publication number
- WO2006062424A2 WO2006062424A2 PCT/PL2005/000071 PL2005000071W WO2006062424A2 WO 2006062424 A2 WO2006062424 A2 WO 2006062424A2 PL 2005000071 W PL2005000071 W PL 2005000071W WO 2006062424 A2 WO2006062424 A2 WO 2006062424A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- animals
- people
- alpha
- growth
- osteo
- Prior art date
Links
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 title claims abstract description 95
- 230000012010 growth Effects 0.000 title claims abstract description 55
- AXFYFNCPONWUHW-UHFFFAOYSA-M 3-hydroxyisovalerate Chemical compound CC(C)(O)CC([O-])=O AXFYFNCPONWUHW-UHFFFAOYSA-M 0.000 title claims abstract description 27
- 241001465754 Metazoa Species 0.000 claims abstract description 94
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 52
- 230000008569 process Effects 0.000 claims abstract description 52
- 238000002360 preparation method Methods 0.000 claims abstract description 48
- 208000020084 Bone disease Diseases 0.000 claims abstract description 45
- 230000035479 physiological effects, processes and functions Effects 0.000 claims abstract description 44
- 235000013305 food Nutrition 0.000 claims abstract description 43
- 229940024606 amino acid Drugs 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 9
- 229930195712 glutamate Natural products 0.000 claims abstract description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 7
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 6
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960003104 ornithine Drugs 0.000 claims abstract description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 4
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 229960000310 isoleucine Drugs 0.000 claims abstract description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000002184 metal Substances 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 235000004554 glutamine Nutrition 0.000 claims abstract 8
- 235000001014 amino acid Nutrition 0.000 claims abstract 6
- 150000002309 glutamines Chemical class 0.000 claims abstract 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 27
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims description 22
- 210000000988 bone and bone Anatomy 0.000 claims description 19
- 230000037396 body weight Effects 0.000 claims description 11
- 208000001132 Osteoporosis Diseases 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000004904 shortening Methods 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 230000001085 cytostatic effect Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000035800 maturation Effects 0.000 claims description 4
- 229940126585 therapeutic drug Drugs 0.000 claims description 4
- 230000007547 defect Effects 0.000 claims description 3
- 238000005115 demineralization Methods 0.000 claims description 3
- 230000002328 demineralizing effect Effects 0.000 claims description 3
- 208000026062 Tissue disease Diseases 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 230000000946 synaptic effect Effects 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000000172 cytosol Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- CABVTRNMFUVUDM-SJBCKIPMSA-N 3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-SJBCKIPMSA-N 0.000 description 1
- 208000010266 Aggressive Periodontitis Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 201000006727 periodontosis Diseases 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008939 stimulatory process Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Definitions
- An object of the invention is the pharmaceutical preparation affecting the processes of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals and the use of the pharmaceutical preparation in the physiological process of the growth and the mineralisation of the osteo-skeletal system and in the osteochondropathy in the matured people and animals.
- Osteoporosis is the generalized disease of the skeleton characterized by a low bone mass and the disturbances in the micro-architecture of the bone tissue and consequently leads to decreased bone strenght and promotes the fractures situated most often in people in the thoracic and lumbar vertebral bodies, in a distal part of the radius and in the neck of the femur. Osteoporosis is the most frequent metabolic disease of bones in people, difficult to diagnose, developing most often asymptomatically for many years, till the first fracture.
- HMB 3-hydroxy-3-metyl-butyrate
- KIC 2-oxo- izo-caproate
- cytosol KIC-dioxygenase This enzyme is present exclusively in the cytosol, while KIC- dehydrogenase appears only in mitochondria.
- endogenic leucm pool is oxidized in that cytosol process.
- the remaining pool of leucin is oxidized in mitochondria.
- a lot of studies showed that HMB is a cholesterol precursor.
- HMB 3-hydroxy-3-metylglutaryl-CoA
- HMB can be a precursor of cellular cholesterol in the muscular tissue in which the synthesis de novo of cholesterol takes place.
- the mechanism of action of HMB is based on the thesis that cells in heavy stress condition or damaged ones are not able for producing sufficient amount of HMG-CoA necessery to maintain cholesterol synthesis.
- HMB administered from outside can be the optimum source of HMG-CoA permitting maintain normal cholesterol synthesis and support cell membranes function. This thesis is confirmed .
- HMB can signifficantly decrease the degree of myocytes damage expressed by decreased outflow of creatine phosphokinase (CPK) from these cells.
- CPK creatine phosphokinase
- the pharmaceutical preparation affecting the processes of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that it is 3-hydroxy-3-methylbutyrate (HMg) and its derivatives including keto-iso-caproic acid (KIC), leucin and isoleucine and is used as a chemical compound in a dose 0.001-1 g/kg/day, alone or in combination with alpha-keto-glutarate (AKG) or/and glutamine or/and glutamate or/and alpha-keto-glutarate of ornithine or/and dipeptides of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and di- and tripeptides of glutamate with other amino acid, or/and mono- and bivalent metal salts and other of alpha-keto-glutarate or/and glutamine or/and glutamate or/and ornithine of alplia-ketoglutarate
- the use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3 -hydroxy ⁇ -jnetyl-butyrate in a dose of 0.0001-0.5 g/kg/day, alone or in combinatin with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and medical food is used as a drug preventing the demineralization and the loss of the osseous tissue mass (osteoporosis) and teeth causing the increase of their mechanical strenght in people and animals.
- AKG alpha-ketoglutarate
- the first other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and the medical food is used as a drug increasing the mineralisation and the mass of osseous tissue and teeth causing the increase of their mechanical strenght in people and animals.
- AKG alpha-ketoglutarate
- the second other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and the medical food is used as drug supporting the healing of the bone fractures and the osseous defects causing the increase of the mechanical strenght of the osseous tissue in people and animals.
- AKG alpha-ketoglutarate
- the third other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a drug supporting the healing of transplants and prosthesis into the osseous tissue. .
- the fourth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as drug a assuring the normal processes of growth and development of the osteo-skeletal system, teeth and joints in people and animals.
- AKG alpha-ketoglutarate
- the fifth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people .and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a drug supporting the repair of damages of the chondral tissue in people and animals.
- AKG alpha-ketoglutarate
- the sixth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG) 3 for producing the curative preparation, functional and medical food is used as a drug preventing the appearance of chondral tissue diseases in people and animals.
- AKG alpha-ketoglutarate
- the seventh other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG) 5 for producing the curative preparation, the functional and the medical food is used as a factor and/or drug increasing the birth body weight in people and animals and accelerating their growth-development.
- AKG alpha-ketoglutarate
- the eighth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor accelerating individual growth and development of farm animals and shortening their production cycle.
- AKG alpha-ketoglutarate
- the ninth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day in combination with AKG in a dose 0.0001-0.5 g/kg/day for producing the curative preparation, functional and medical food is used as a factor and/or drug enlarging the birth body weight and accelerating the growth in people and animals.
- the tenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as drug preventing the incidence of too low body weight and increasing the birth body weight of prematured newborns in people and animals.
- AKG alpha-ketoglutarate
- the eleventh other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as an . immunostimulating factor in prematured and matured newborns after vaginal and caesarean delivery in people and animals.
- the twelfth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor stimulating the development and maturation of the alimentary canal in people and animals.
- AKG alpha-ketoglutarate
- the thirteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor regulating the processes on the way of the alimentary-osseous axis in people and animals.
- AKG alpha-ketoglutarate
- the fourteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a drug maintaining optimal development of the central nervous system and its neuronal and synaptic structures in people and animals.
- AKG alpha-ketoglutarate
- the fifteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as anti- apoptotic and anti-degeneration drug for the structures of nervous and the osseous system in people and animals.
- AKG alpha-ketoglutarate
- the sixteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001- 0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used prenatally in pregnant animal and human females for the induction of the general, systemic, organ and cellular processes of development and maturation assuring the optimal functional adaptation in the neonatal period in people and animals.
- AKG alpha-ketoglutarate
- the seventeenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a drug supporting the development and the growth of the osteo-skeletal system in prematured neonates in people and animals.
- AKG alpha-ketoglutarate
- the eighteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor inhibiting and preventing the negative effects of therapeutic drugs (glicocorticoids, cytostatics, antibiotics, etc.) on the nervous systen in people and animals.
- therapeutic drugs glicocorticoids, cytostatics, antibiotics, etc.
- the nineteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor inhibiting and preventing the negative effects of therapeutic drugs (glicocorticoids, cytostatics, antibiotics etc) on the osteo-skeletal systen in people and animals.
- therapeutic drugs glicocorticoids, cytostatics, antibiotics etc
- the preparation obtained accordingly to the invention is especially used in viands or drugs to prevent the decrease of the osseous mass during osteporosis and arthrosis treatment as well as to increase the mass, mineralisation and mechanical strenghts of the osseous tissue, teeth, chondral tissue in people and animals for the purpose of prevention and treatment diseases of the osseous tissue, such osteoporosis, osteopenia and others, chondral tissue, such arthrosis and others and joint diseases, such rheumatism and dental diseases, such the caries, periodontosis and others, as well as for the purpose of assuring the normal development of the osteo-skeletal system and teeth with supporting the healing of defects, degeneracies and fractures of the osseous and chondral tissue, supporting the healing of the osseous transplants and prosthesis and used prenatally in the pregnant females for the purpose of increasing the birth body weight of vertebrata (people and animals) and shortening of the production cycle of farm animals.
- HMB 3-hydroxy-3- methylbutyrate
- AKG alpha-ketoglutarate
- KIC keto-isokaproic acid
- leucin and isoleucin are a factor stimulating processes of growth and development of the osteo-skeletal system in people and animals and increasing the mineralisation and the mechanical strenght of the bones. It prevents demineralization and the loss of the osseous tissue mass and related "decrease of its mechanical strenght leading to osteoporosis as well as increases the mass of the osseous tissue, its mineralisation and the mechanical strenght in the presence of osteopenia in people and animals.
- HMB shows the activity preventing the occurrence of diseases and damages of the chondral tissue and helps its regeneration in people and animals.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention dissolves the problem of the pharmaceutical preparation affecting the processes of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals. The essence of the invention is that 3-hydroxy-3-methylbutyrate (HMB) and its derivatives such keto-isokaproic acid (KIC) and leucin and isoleucine are used as chemical compound in a dose 0.001-1 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG) or/and glutamines or/and glutamate or/and alpha- ketoglutarate of ornithine or/and dipeptides of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and di- and tripeptides of glutamate with other amino acid, or/and mono- and bivalent metal salts and other alpha-keto of glutarate or/and glutamine or/and glutamate or/and ornithine of alpha-ketoglutarate, in a dose 0.001-1 g/kg/day for producing of the curative preparation, functional and medical food.
Description
USE OF 3-HYDROXY-3-METHYLBUTYRATE ALONE OR IN COMBINATION WITH
ALPHA-KETOGLUTARATE IN THE PHYSIOLOGICAL BONE GROWTH AND
MINERALISATION AND IN THE OSTEOCHONDROPATHY
An object of the invention is the pharmaceutical preparation affecting the processes of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals and the use of the pharmaceutical preparation in the physiological process of the growth and the mineralisation of the osteo-skeletal system and in the osteochondropathy in the matured people and animals.
After obtaining the skeletal maturity in processes of the osseous turnover the resorption begins to predominate over the synthesis, the osseous mass and density decrease leading, with the intensification of this process, to osteoporosis. Osteoporosis is the generalized disease of the skeleton characterized by a low bone mass and the disturbances in the micro-architecture of the bone tissue and consequently leads to decreased bone strenght and promotes the fractures situated most often in people in the thoracic and lumbar vertebral bodies, in a distal part of the radius and in the neck of the femur. Osteoporosis is the most frequent metabolic disease of bones in people, difficult to diagnose, developing most often asymptomatically for many years, till the first fracture. The role of nutritional and growth factors is actually of a great importance because of cognitive and practical regards targeting for the elimination of losses (deaths) among young animals, especially in the peri-separation period. Somatotropin and somatomedines (IGF-I, IGF-H), estrogens and androgens are well-known hormonal growth stimulators. For normal body and osteo-skeletal system growth the feedback system between somatotropin and insulin-like growth factors is necessary.
Well-known is 3-hydroxy-3-metyl-butyrate (HMB) which is a metabolite of the amino acid leucin. It is produced endogenously in human' and animals'
organisms. A first stage in the leucin metabolism is the transamination into 2-oxo- izo-caproate (KIC). Then KIC is transformed into HMB in the presence of cytosol KIC-dioxygenase. This enzyme is present exclusively in the cytosol, while KIC- dehydrogenase appears only in mitochondria. In physiological state only approximately 5% of endogenic leucm pool is oxidized in that cytosol process. The remaining pool of leucin is oxidized in mitochondria. A lot of studies showed that HMB is a cholesterol precursor. In the cytosol of liver and muscle cells HMB is first converted into 3-hydroxy-3-metylglutaryl-CoA (HMG-CoA) which can be used then for the synthesis of cholesterol. HMB can be a precursor of cellular cholesterol in the muscular tissue in which the synthesis de novo of cholesterol takes place. The mechanism of action of HMB is based on the thesis that cells in heavy stress condition or damaged ones are not able for producing sufficient amount of HMG-CoA necessery to maintain cholesterol synthesis. Thus HMB administered from outside can be the optimum source of HMG-CoA permitting maintain normal cholesterol synthesis and support cell membranes function. This thesis is confirmed . by observation that the administration of HMB can signifficantly decrease the degree of myocytes damage expressed by decreased outflow of creatine phosphokinase (CPK) from these cells. The improve in lipid plasma profile, the normalization of blood pressure and the improve of the function of cardiovascular system after HMB administration were observed in the clinical research. Many studies performed on physically active people showed that the administration of HMB improves the muscular function, increases the muscular mass and reduces the adipose tissue signifficantly better in coaching people than in people subjected to the same training but not taking the preparation. This is caused by protective activity of HMB to the muscles leading to the decrease of myocytes damage. Results of perfoπned on people 11 published clinical research prove that the administration of HMB does not have any undesirable side effects in men, women, adolescents and old people as long as a daily dose doesn't exceed 3g.
The pharmaceutical preparation affecting the processes of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the
osteochondropathy in the matured people and animals distinguishes itself that it is 3-hydroxy-3-methylbutyrate (HMg) and its derivatives including keto-iso-caproic acid (KIC), leucin and isoleucine and is used as a chemical compound in a dose 0.001-1 g/kg/day, alone or in combination with alpha-keto-glutarate (AKG) or/and glutamine or/and glutamate or/and alpha-keto-glutarate of ornithine or/and dipeptides of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and di- and tripeptides of glutamate with other amino acid, or/and mono- and bivalent metal salts and other of alpha-keto-glutarate or/and glutamine or/and glutamate or/and ornithine of alplia-ketoglutarate, in a dose 0.001-1 g/kg/day for producing the curative preparation, functional and medical food.
The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3 -hydroxy^ -jnetyl-butyrate in a dose of 0.0001-0.5 g/kg/day, alone or in combinatin with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and medical food is used as a drug preventing the demineralization and the loss of the osseous tissue mass (osteoporosis) and teeth causing the increase of their mechanical strenght in people and animals.
The first other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and the medical food is used as a drug increasing the mineralisation and the mass of osseous tissue and teeth causing the increase of their mechanical strenght in people and animals.
The second other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the
pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and the medical food is used as drug supporting the healing of the bone fractures and the osseous defects causing the increase of the mechanical strenght of the osseous tissue in people and animals.
The third other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a drug supporting the healing of transplants and prosthesis into the osseous tissue. .
The fourth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as drug a assuring the normal processes of growth and development of the osteo-skeletal system, teeth and joints in people and animals.
The fifth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people .and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a drug supporting the repair of damages of the chondral tissue in people and animals.
The sixth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the
pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG)3 for producing the curative preparation, functional and medical food is used as a drug preventing the appearance of chondral tissue diseases in people and animals.
. The seventh other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG)5 for producing the curative preparation, the functional and the medical food is used as a factor and/or drug increasing the birth body weight in people and animals and accelerating their growth-development.
The eighth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor accelerating individual growth and development of farm animals and shortening their production cycle.
The ninth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day in combination with AKG in a dose 0.0001-0.5 g/kg/day for producing the curative preparation, functional and medical food is used as a factor and/or drug enlarging the birth body weight and accelerating the growth in people and animals.
The tenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the
pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as drug preventing the incidence of too low body weight and increasing the birth body weight of prematured newborns in people and animals.
The eleventh other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as an . immunostimulating factor in prematured and matured newborns after vaginal and caesarean delivery in people and animals.
The twelfth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor stimulating the development and maturation of the alimentary canal in people and animals.
The thirteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor regulating the processes on the way of the alimentary-osseous axis in people and animals.
The fourteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology
and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a drug maintaining optimal development of the central nervous system and its neuronal and synaptic structures in people and animals.
The fifteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as anti- apoptotic and anti-degeneration drug for the structures of nervous and the osseous system in people and animals.
The sixteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001- 0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used prenatally in pregnant animal and human females for the the induction of the general, systemic, organ and cellular processes of development and maturation assuring the optimal functional adaptation in the neonatal period in people and animals.
The seventeenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a drug
supporting the development and the growth of the osteo-skeletal system in prematured neonates in people and animals.
The eighteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor inhibiting and preventing the negative effects of therapeutic drugs (glicocorticoids, cytostatics, antibiotics, etc.) on the nervous systen in people and animals.
The nineteenth other use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals is that the pharmaceutical preparation containing 3-hydroxy-3-methylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor inhibiting and preventing the negative effects of therapeutic drugs (glicocorticoids, cytostatics, antibiotics etc) on the osteo-skeletal systen in people and animals.
The preparation obtained accordingly to the invention is especially used in viands or drugs to prevent the decrease of the osseous mass during osteporosis and arthrosis treatment as well as to increase the mass, mineralisation and mechanical strenghts of the osseous tissue, teeth, chondral tissue in people and animals for the purpose of prevention and treatment diseases of the osseous tissue, such osteoporosis, osteopenia and others, chondral tissue, such arthrosis and others and joint diseases, such rheumatism and dental diseases, such the caries, periodontosis and others, as well as for the purpose of assuring the normal development of the osteo-skeletal system and teeth with supporting the healing of defects, degeneracies and fractures of the osseous and chondral tissue, supporting the healing of the osseous transplants and prosthesis and used prenatally in the
pregnant females for the purpose of increasing the birth body weight of vertebrata (people and animals) and shortening of the production cycle of farm animals.
The object of the invention is presented in examples on the base of performed experiences . Experience 1
The preparation containing 3-hydroxy-3-methylbutyrate was administered per os to sows for 14 days ante partum in a dose 2 g. The increase of the birth body weight of young pigs, the stimulation of the growth-development processes in the neonatal period and the shortening of the production cycle of animals were observed. Results:
Experience 2
The administration of the preparation containing 3-hydro-3-methylbutyrate in a dose 2g/sow in combination with AKG in a dose 0.4g/kg, both for 14 days ante partum, increases the birth body weight of young pigs and accelerates their growth and development in the neonatal period shortening simultaneously the duration of the production cycle. Results
Experience 3
Besides the administration of the preparation containing 3-hydro-3- metylbutyrate to turkeys in the post-hutching period in a dose 0.05g/kg increases the mass, the degree of mineralisation, geometrical properties and mechanical strenghts of the ulna.
Results
The research being the object of the invention shoved that 3-hydroxy-3- methylbutyrate (HMB) used alone or in combination with alpha-ketoglutarate (AKG) and its derivatives such keto-isokaproic acid (KIC), leucin and isoleucin are a factor stimulating processes of growth and development of the osteo-skeletal system in people and animals and increasing the mineralisation and the mechanical strenght of the bones. It prevents demineralization and the loss of the osseous tissue mass and related "decrease of its mechanical strenght leading to osteoporosis as well as increases the mass of the osseous tissue, its mineralisation and the mechanical strenght in the presence of osteopenia in people and animals. Besides anabolic activity on the osseous tissue, HMB shows the activity preventing the occurrence of diseases and damages of the chondral tissue and helps its regeneration in people and animals.
Claims
1. The pharmaceutical preparation affecting the processes of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself itself that containing 3-hydroxy-3-methylbutyrate (HMB) and its derivatives, such keto-isokaproic acid (KIC) and leucin and isoleucine is used as a chemical compound in a dose 0.001-1 g/kg/d, alone or in combination with alpha-ketoglutarate (AKG) or/and glutamines or/and glutamate or/and alpha-ketoglutarate of ornithine or and dipeptides of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and di- and tripeptides of glutamate with other amino acid, or/and mono- and bivalent metal salts and other alpha-keto of glutarate or/and glutamines or/and glutamate or/and ornithine of alpha- ketoglutarate, in a dose 0.001-1 g/kg/day for producing the curative preparation, functional and medical food.
2. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate ( AKG ), for producing the curative preparation, the functional and medical food is used as a drug preventing the demineralization and the loss of the mass of the osseous tissue (osteoporosis) and teeth causing the increase of their mechanical strenght in people and animals.
3. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical foods is used as drug increasing the mineralisation and the mass of the osseous tissue and teeth causing the increase of its mechanical strenght in people and animals.
4. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and medical food is used as a drug supporting healing the fractures and defects of bones causing the increase of the mechanical strenght of the osseous tissue in people and animals.
5. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and medical food is used as a drug supporting the healing of transplants and prosthesis into the osseous tissue.
6. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and medical food is used as a drug supporting the regularity of growth-development processes of the osteo- skeletal system, teeth and joints in people and animals.
7. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and medical food is used as a drug helping the repair of chondral tissue damages in people and animals.
8. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and medical food is used as a drug preventing the occurrence of chondral tissue diseases in people and animals.
9. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and medical food is used as a factor and/or drug increasing the birth body weight in people and animals and accelerating their development.
10. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and medical food is used as a factor accelerating individual growth and development of farm animals and shortening their production cycle.
11. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day in combination with AKG in a dose 0.0001-0.5 g/kg/day for producing the curative preparation, the functional and medical food is used as a factor and/or a drug increasing the birth body weight in people and animals and accelerating their development.
12. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, the functional and medical food is used as a drug preventing the occurrence of too low birth body weight and increasing the birth body weight of prematured neonates in people and animals.
13. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as the immunostimulating factor in prematured and matured neonates after vaginal and caesarean delivery in people and animals.
14. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor stimulating the development and maturation of the alimentary system in people and animals.
15. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as the factor regulating the reactions of alimentary-osseous axis in people arid animals.
16. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a drug maintaining the optimum development of the central nervous system and its neuronal and synaptic structures in people and animals.
17. The pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a drug preventing the apoptoic and degeneration changes in structures of the nervous and osseous system in people and animals.
18. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used prenatally in pregnant animal and human females for induction of the general, systemic, organ and cellular developmental and maturation processes assuring optimum adapting functional abilities in the neonatal period in people and animals.
19. The pharmaceutical preparation affecting the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a drug supporting development and growth of the osteo-skeletal system in prematured newborns in people and animals.
20. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and the in osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as a factor inhibiting and preventing the negative effects of therapeutic drugs (glicocorticoids, cytostatics, antibiotics etc) on the nervous system in people and animals. - -
21. The use of the pharmaceutical preparation in the process of the growth and the mineralisation of the osteo-skeletal system in the physiology and in the osteochondropathy in the matured people and animals distinguishes itself that containing 3-hydroxy-3-metylbutyrate in a dose 0.0001-0.5 g/kg/day, alone or in combination with alpha-ketoglutarate (AKG), for producing the curative preparation, functional and medical food is used as the factor inhibiting and preventing the negative effects of therapeutic drugs (glicocorticoids, cytostatics, antibiotics etc) on the osteo-skeletal system in people and animals.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL371081A PL371081A1 (en) | 2004-11-08 | 2004-11-08 | Pharmaceutical compound with the effect on the growth and the mineralization of osseous-skeleton system and on mature years bone and cartilage diseases among humans and animals, and method for its application |
| PLP.371081 | 2004-11-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006062424A2 true WO2006062424A2 (en) | 2006-06-15 |
| WO2006062424A3 WO2006062424A3 (en) | 2007-02-15 |
Family
ID=35825427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/PL2005/000071 WO2006062424A2 (en) | 2004-11-08 | 2005-11-07 | Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system |
Country Status (2)
| Country | Link |
|---|---|
| PL (1) | PL371081A1 (en) |
| WO (1) | WO2006062424A2 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007058612A1 (en) * | 2005-11-15 | 2007-05-24 | Entress Ab | Medicament for use in connection with cartilage impairment |
| WO2008122613A2 (en) * | 2007-04-04 | 2008-10-16 | Evonik Degussa Gmbh | Food supplement containing alpha-keto acids |
| WO2012112419A1 (en) * | 2011-02-17 | 2012-08-23 | Abbott Laboratories | Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate |
| ES2421187A1 (en) * | 2012-02-23 | 2013-08-29 | Abbott Laboratories | Method for improving cerebral development and cognitive function using beta-hydroxy-beta-methylbutyrate (Machine-translation by Google Translate, not legally binding) |
| US8609725B2 (en) | 2004-03-26 | 2013-12-17 | Abbott Laboratories | Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate |
| US8778992B2 (en) | 2005-12-19 | 2014-07-15 | Abbott Laboratories | Method of using beta-hydroxy-beta-methylbutyrate to treat allergies and asthma |
| US8916217B2 (en) | 2010-01-29 | 2014-12-23 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising HMB |
| US9241508B2 (en) | 2010-01-29 | 2016-01-26 | Abbott Laboratories | Nutritional emulsions comprising calcium HMB |
| US9521859B2 (en) | 2010-06-10 | 2016-12-20 | Normanella T. Dewille | Substantially clear nutritional liquids comprising calcium HMB and soluble protein |
| US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
| JP2018531228A (en) * | 2015-09-16 | 2018-10-25 | メタボリック・テクノロジーズ，インコーポレーテッド | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4883817A (en) * | 1987-03-02 | 1989-11-28 | Iowa State University Research Foundation, Inc. | Raising chickens for meat production with ketoisocaproate-containing feeds |
| US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| WO1994017678A1 (en) * | 1993-02-11 | 1994-08-18 | Iowa State University Research Foundation, Inc. | Method of enhancing nutritional value of colostrum and first milk of pregnant mammals |
| WO2003043626A1 (en) * | 2001-11-23 | 2003-05-30 | Essentys Ab | Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis |
| WO2003049687A2 (en) * | 2001-12-06 | 2003-06-19 | Weller Health, Inc. | Medicinal compositions & therapeutic methods |
| US20040071825A1 (en) * | 2002-10-15 | 2004-04-15 | Christopher Lockwood | Agglomerated granular protein-rich nutritional supplement |
| US20040220266A1 (en) * | 2002-09-09 | 2004-11-04 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
| WO2005102301A2 (en) * | 2004-03-26 | 2005-11-03 | Abbott Laboratories | Hydroxymethylbutyrate compositions and uses thereof |
-
2004
- 2004-11-08 PL PL371081A patent/PL371081A1/en unknown
-
2005
- 2005-11-07 WO PCT/PL2005/000071 patent/WO2006062424A2/en active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4883817A (en) * | 1987-03-02 | 1989-11-28 | Iowa State University Research Foundation, Inc. | Raising chickens for meat production with ketoisocaproate-containing feeds |
| US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| WO1994017678A1 (en) * | 1993-02-11 | 1994-08-18 | Iowa State University Research Foundation, Inc. | Method of enhancing nutritional value of colostrum and first milk of pregnant mammals |
| WO2003043626A1 (en) * | 2001-11-23 | 2003-05-30 | Essentys Ab | Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis |
| WO2003049687A2 (en) * | 2001-12-06 | 2003-06-19 | Weller Health, Inc. | Medicinal compositions & therapeutic methods |
| US20040220266A1 (en) * | 2002-09-09 | 2004-11-04 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
| US20040071825A1 (en) * | 2002-10-15 | 2004-04-15 | Christopher Lockwood | Agglomerated granular protein-rich nutritional supplement |
| WO2005102301A2 (en) * | 2004-03-26 | 2005-11-03 | Abbott Laboratories | Hydroxymethylbutyrate compositions and uses thereof |
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8785496B2 (en) | 2004-03-26 | 2014-07-22 | Abbott Laboratories | Method of using beta-hydroxy-beta-methylbutyrate for treating disease-associated wasting |
| US8785495B2 (en) | 2004-03-26 | 2014-07-22 | Abbott Laboratories | Compositions including beta-hydroxy-beta-methylbutyrate |
| US8778993B2 (en) | 2004-03-26 | 2014-07-15 | Abbott Laboratories | Method of using β-hydroxy-β-methylbutyrate for the treatment of disease conditions |
| US8778994B2 (en) | 2004-03-26 | 2014-07-15 | Abbott Laboratories | Method of using beta-hydroxy-beta-methylbutyrate and fatty acids for treating disease-associated wasting |
| US8609725B2 (en) | 2004-03-26 | 2013-12-17 | Abbott Laboratories | Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate |
| WO2007058612A1 (en) * | 2005-11-15 | 2007-05-24 | Entress Ab | Medicament for use in connection with cartilage impairment |
| US8778992B2 (en) | 2005-12-19 | 2014-07-15 | Abbott Laboratories | Method of using beta-hydroxy-beta-methylbutyrate to treat allergies and asthma |
| US8796333B2 (en) | 2005-12-19 | 2014-08-05 | Abbott Laboratories | Method of using β-hydroxy-β-methylbutyrate to treat a condition |
| WO2008122613A3 (en) * | 2007-04-04 | 2009-06-04 | Evonik Degussa Gmbh | Food supplement containing alpha-keto acids |
| WO2008122473A3 (en) * | 2007-04-04 | 2009-04-23 | Evonik Degussa Gmbh | Food supplement containing alpha-keto acids |
| WO2008122473A2 (en) * | 2007-04-04 | 2008-10-16 | Evonik Degussa Gmbh | Food supplement containing alpha-keto acids |
| WO2008122613A2 (en) * | 2007-04-04 | 2008-10-16 | Evonik Degussa Gmbh | Food supplement containing alpha-keto acids |
| US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
| US9241508B2 (en) | 2010-01-29 | 2016-01-26 | Abbott Laboratories | Nutritional emulsions comprising calcium HMB |
| US8916217B2 (en) | 2010-01-29 | 2014-12-23 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising HMB |
| US9521859B2 (en) | 2010-06-10 | 2016-12-20 | Normanella T. Dewille | Substantially clear nutritional liquids comprising calcium HMB and soluble protein |
| CN103347406A (en) * | 2011-02-17 | 2013-10-09 | 雅培制药有限公司 | Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate |
| CN103347406B (en) * | 2011-02-17 | 2015-08-05 | 雅培制药有限公司 | Beta-hydroxy-Beta-methyl butyrate is used to improve the method for brain development and cognitive function |
| JP2014506890A (en) * | 2011-02-17 | 2014-03-20 | アボット・ラボラトリーズ | Method for improving brain development and cognitive function using β-hydroxy-β-methylbutyrate |
| US9326956B2 (en) | 2011-02-17 | 2016-05-03 | Abbott Laboratories | Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate |
| TWI565420B (en) * | 2011-02-17 | 2017-01-11 | 亞培公司 | Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate |
| JP2017061483A (en) * | 2011-02-17 | 2017-03-30 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | METHODS FOR IMPROVING BRAIN DEVELOPMENT AND COGNITIVE FUNCTION USING β-HYDROXY-β-METHYLBUTYRATE |
| WO2012112419A1 (en) * | 2011-02-17 | 2012-08-23 | Abbott Laboratories | Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate |
| ES2421187A1 (en) * | 2012-02-23 | 2013-08-29 | Abbott Laboratories | Method for improving cerebral development and cognitive function using beta-hydroxy-beta-methylbutyrate (Machine-translation by Google Translate, not legally binding) |
| JP2018531228A (en) * | 2015-09-16 | 2018-10-25 | メタボリック・テクノロジーズ，インコーポレーテッド | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma |
| US10758504B2 (en) * | 2015-09-16 | 2020-09-01 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma |
| AU2016323779B2 (en) * | 2015-09-16 | 2022-03-17 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma |
| EP3349745B1 (en) * | 2015-09-16 | 2023-12-13 | Metabolic Technologies, LLC | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for enhancing recovery from soft tissue trauma |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006062424A3 (en) | 2007-02-15 |
| PL371081A1 (en) | 2006-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006062424A2 (en) | Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system | |
| RU2751638C2 (en) | Compositions containing nicotine amidriboside and urolitin | |
| JP2925326B2 (en) | Methods for promoting human nitrogen retention | |
| WO2014019268A1 (en) | Pharmaceutical composition for promoting nerve injury restoration and application thereof | |
| JP2012529469A (en) | Niacin and / or trigonelline as muscle stimulants | |
| JP2007504182A (en) | Compositions and methods for promoting bone healing | |
| RU2423120C2 (en) | No donor and dithiolane-containing compositions and their application for improvement of sexual function | |
| WO2006133055A2 (en) | Method and composition for increasing the alkalinity of the body | |
| JP6944221B2 (en) | Composition for prevention, amelioration or treatment of bone loss disease containing CHP (cyclo-hispro) | |
| EP3508201A2 (en) | Glycine as a diet supplement for use in the treatment skin problems that result from underlying collagen disorders and and cosmetic uses thereof | |
| CN108815505B (en) | Composition for improving bone density and bone joint function of middle-aged and elderly people and avoiding lumbar and leg cramps | |
| US20200030349A1 (en) | Physiologically active preparation comprising n-acetyl-glucosamine for the treatment of back pain | |
| JP7271016B2 (en) | Use of a composition containing CHP (cyclo-hyspro) and parathyroid hormone for the prevention, amelioration or treatment of bone loss diseases | |
| CN105707397A (en) | Heathy vitamin candy | |
| US9533946B1 (en) | N-carbamoylputrescine to enhance muscle protein synthesis | |
| WO2005123059A1 (en) | Alpha-ketoglutatic acid or derivatives thereof for the treatment of osteoporosis and related diseases | |
| RU2721605C1 (en) | Pharmaceutical composition for parenteral drop introduction | |
| ES2292495T3 (en) | STIMULATING COMPOSITION FOR WEIGHT GAIN, PROCEDURE AND PRODUCT. | |
| WO2008066715A2 (en) | Method of treatment using aspergillus oryzae protease | |
| RU2277929C2 (en) | Method for making human organism healthy | |
| RU2120297C1 (en) | Method of normalization of metabolic processes in cell and a preparation for these aims | |
| UA140755U (en) | METHOD OF TREATMENT OF LIVER FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOGEPATITIS BY COMORBIDITY WITH OBESITY AND OSTEOARTHRITIS | |
| CN114748610A (en) | Application of osteocalcin in preparing anti-inflammatory medicine | |
| CN114028535A (en) | Selenium-rich earthworm protein composition for promoting fracture healing and preparation method thereof | |
| JP2023032210A (en) | Antiinflammatory agent for joint synovial membrane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05802510 Country of ref document: EP Kind code of ref document: A2 |